Market Overview

UPDATE: Dawson James Initiates Coverage on Ariad Pharmaceuticals with Market Outperform Rating, $32 PT

Related ARIA
JMP Securities Downgrades Ariad, Cites Limited Near-Term Upside In Light Of Prescription Trends
The Market In 5 Minutes: UA, GM, P&G Earnings On The Street's Mind
Bernie Sanders's Destruction Of Ariad (Seeking Alpha)

In a report published Friday, Dawson James initiated coverage on Ariad Pharmaceuticals (NASDAQ: ARIA) with a Market Outperform rating and $32.00 price target.

Dawson James noted, “We are initiating coverage of Ariad Pharmaceuticals with a Market Outperform rating and a twelve-month price target of $32. Ariad is a developer of differentiated cancer medicines characterized by best-in-class properties such as efficacy, safety/tolerability and patient convenience. Ariad is developing two compounds with blockbuster potential: ponatinib, for the treatment of chronic myeloid leukemia (CML) and AP26113 (‘113) for the treatment of ALK- and EGFR-positive non-small cell lung cancer (NSCLC). Ariad represents a rare investment opportunity in the biotechnology space - that of a self-sufficient, fully integrated company that develops and markets its own products on a worldwide basis. In many ways, Ariad reminds us of Celgene (CELG, Market Outperform) in the early years of the development of Revlimid, with similar longterm potential.”

Ariad Pharmaceuticals closed on Thursday at $21.91.

Latest Ratings for ARIA

Oct 2016JMP SecuritiesDowngradesMarket OutperformMarket Perform
Oct 2016JP MorganDowngradesNeutralUnderweight
Oct 2016SunTrust Robinson HumphreyInitiates Coverage onBuy

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Dawson JamesAnalyst Color Initiation Analyst Ratings


Related Articles (ARIA)

View Comments and Join the Discussion!